tradingkey.logo

Beta Bionics Inc

BBNX
View Detailed Chart
28.820USD
+1.330+4.84%
Close 11/11, 16:00ETQuotes delayed by 15 min
1.27BMarket Cap
LossP/E TTM

Beta Bionics Inc

28.820
+1.330+4.84%
Intraday
1m
30m
1h
D
W
M
D

Today

+4.84%

5 Days

+3.63%

1 Month

+37.04%

6 Months

+106.59%

Year to Date

0.00%

1 Year

0.00%

View Detailed Chart

TradingKey Stock Score of Beta Bionics Inc

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Beta Bionics Inc's Score

Industry at a Glance

Industry Ranking
26 / 209
Overall Ranking
88 / 4608
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 10 analysts
Buy
Current Rating
31.300
Target Price
+13.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Beta Bionics Inc Highlights

StrengthsRisks
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 36282.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 65.12M.
Undervalued
The company’s latest PE is -14.84, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 48.08M shares, increasing 10.32% quarter-over-quarter.
Held by First Eagle Investment
Star Investor First Eagle Investment holds 200.51K shares of this stock.

Beta Bionics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Beta Bionics Inc Info

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Ticker SymbolBBNX
CompanyBeta Bionics Inc
CEOMr. Sean Saint
Websitehttps://www.betabionics.com
KeyAI